Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Metagenomi, Inc. before investing.

In this article, we go over a few key elements for understanding Metagenomi, Inc.’s stock price such as:

• Metagenomi, Inc.’s current stock price and volume
• Why Metagenomi, Inc.’s stock price changed recently
• Upgrades and downgrades for MGX from analysts
• MGX’s stock price momentum as measured by its relative strength

About Metagenomi, Inc. (MGX)

Before we jump into Metagenomi, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer. Metagenomi, Inc. was incorporated in 2016 and is headquartered in Emeryville, California.

Want to learn more about Metagenomi, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Metagenomi, Inc..

Metagenomi, Inc.’s Stock Price as of Market Close

As of December 02, 2025, 11:31 AM, CST, Metagenomi, Inc.’s stock price was $1.570.

Metagenomi, Inc. is down 1.88% from its previous closing price of $1.600.

During the last market session, Metagenomi, Inc.’s stock traded between $1.560 and $1.640. Currently, there are approximately 37.35 million shares outstanding for Metagenomi, Inc..

Metagenomi, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Metagenomi, Inc. Stock Price History

Metagenomi, Inc.’s (MGX) price is currently down 10.29% so far this month.

During the month of December, Metagenomi, Inc.’s stock price has reached a high of $1.790 and a low of $1.560.

Over the last year, Metagenomi, Inc. has hit prices as high as $4.920 and as low as $1.230. Year to date, Metagenomi, Inc.’s stock is down 56.51%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Metagenomi, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 01, 2025, there was 1 analyst who downgraded Metagenomi, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Metagenomi, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Metagenomi, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Metagenomi, Inc.’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Metagenomi, Inc. (MGX) by visiting AAII Stock Evaluator.

Relative Price Strength of Metagenomi, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 01, 2025, Metagenomi, Inc. has a weighted four-quarter relative price strength of -7.14%, which translates to a Momentum Score of 34 and is considered to be Weak.

Want to learn more about how Metagenomi, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Metagenomi, Inc. Stock Price: Bottom Line

As of December 2, 2025, Metagenomi, Inc.’s stock price is $1.570, which is down 1.88% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Metagenomi, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.